Capricor Therapeutics closes the July 4 week at $23.21 — down 24% on the month, 24% on the week — with the short position still near multi-month highs and the August 6 earnings date drawing closer.
The structural short story hasn't changed, but there are early signs of partial relief. Bears hold 28.4% of the free float — roughly 13 million shares — up 3.8% on the week and 19% over the past month. That monthly build remains the dominant trend. However, Thursday's data showed a sharp single-session drop of 10.7%, pulling shares short from 14.5 million back to 13.0 million. The ORTEX short score has eased to 76.7 from the 79.5 peak hit on June 30, continuing the mild drift lower flagged in the July 4 article. The score is still high — ranking in just the 6th percentile of the universe on the short score rank factor — but the directional move is a modest softening. The borrow market remains the enduring contradiction in this setup: cost to borrow is 0.57%, lower than a week ago and barely above where it has traded all month. Availability is relatively loose at 179%, meaning there are nearly two shares available for every one currently lent out. That is tight compared to the 349% reading in late May, but it is far from a squeeze setup. Bears are building a heavy position at a rock-bottom cost, which continues to be the puzzle at the heart of this trade.
The options market offers no additional conviction in either direction. The put/call ratio is 0.38 — right in line with its 20-day average of 0.38, with a z-score barely above zero. After the brief uptick in put demand on June 29-30 (PCR nudged to 0.42), activity has reverted to neutral. The 52-week high on the PCR is 3.16, making the current reading look almost indifferent. There is no hedging signal here — options traders are neither protecting against further downside nor positioning for a reversal.
The institutional picture adds texture. Suvretta Capital Management and Tang Capital Management each added meaningful positions in Q1, with Tang doubling its stake by 1.7 million shares. BlackRock also added 570,000 shares as recently as June 30, and State Street Global Advisors added 1.35 million shares through May. These are not panic sellers. Point72, by contrast, trimmed over 1 million shares in Q1. The insider flow runs the other way: the CFO and General Counsel sold across June 22, 24, and 25 at prices of $30.00–$30.38 — well above the current close — and the net insider flow across 90 days amounts to $8.4 million in sales with no purchases recorded. Those sales, timed near the recent range high before the stock fell a further 24%, stand as notable context heading into the August print.
Peer performance this week underscores how isolated CAPR's decline has been. SLDB gained 22% on the week. ABEO added 15%. DYN rose 12%. All three are correlated clinical-stage names. CAPR's 24% weekly loss is a sharp divergence from a cohort that is broadly rallying — either CAPR-specific news is driving the gap, or the heavy short position is creating selling pressure that peers without comparable bear interest are not facing.
The August 6 earnings date is now the clearest waypoint. The last earnings print in May produced a 5% next-day decline and a 16% five-day decline, so the stock's recent history around results skews negative. With 13.7 days to cover per the FINRA settlement data, bears cannot unwind quickly if sentiment turns — and with institutional holders still adding at Q1 levels, the configuration into that print is one to watch closely.
See the live data behind this article on ORTEX.
Open CAPR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
